Boster Immunoleader

antibody

Anti-SerpinB2 Antibody

PB9355

100 ug/vial

240 USD

polyclonal

rabbit

western blot, immunohistochemistry - paraffin section

Anti-SerpinB2 Antibody

PB9355

Polyclonal

Rabbit IgG polyclonal antibody for Plasminogen activator inhibitor 2(SERPINB2) detection. Tested with WB, IHC-P in Human.

240 USD

Rabbit IgG

100 ug/vial

Lyophilized

No cross reactivity with other proteins.

Reacts with: human

WB,IHC-P

Concentration: 0.1-0.5μg/ml; Tested Species: Human

Concentration: 0.5-1μg/ml; Tested Species: Human

WB: The detection limit for SerpinB2 is approximately 0.1ng/lane under reducing conditions. Tested Species: In-house tested species with positive results. By Heat: Boiling the paraffin sections in 10mM citrate buffer, pH6.0, for 20mins is required for the staining of formalin/paraffin sections. Other applications have not been tested. Optimal dilutions should be determined by end users.

E.coli-derived human SerpinB2 recombinant protein (Position: M1-K180). Human SerpinB2 shares 70% and 66% amino acid (aa) sequence identity with mouse and rat SerpinB2, respectively.

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg NaN3.

Immunogen affinity purified.

Add 0.2ml of distilled water will yield a concentration of 500ug/ml.

At -20˚C for one year. After reconstitution, at 4˚C for one month. It can also be aliquotted and stored frozen at -20˚C for a longer time. Avoid repeated freezing and thawing.

Boster provides a series of assays reacted with primary antibodies. Antibody can be supported by chemiluminescence kit EK1002 in WB, supported by SA1022 in IHC(P).

SERPINB2 is also known as PAI or PAI2. Plasminogen activator inhibitor-2 (placental PAI) is acoagulation factor that inactivates tPA and urokinase. It is present in most cells, especially monocytes/macrophages. PAI-2 exists in two forms, a 60-kDa extracellular glycosylated form and a 43-kDa intracellular form. It is present only at detectable quantities in blood during pregnancy, as it is produced by the placenta, and may explain partially the increased rate of thrombosisduring pregnancy. The majority of expressed PAI-2 remains unsecreted due to the presence of an inefficient internal signal peptide.

1. Corsetti JP, et al. Plasminogen activator inhibitor-2 polymorphism associates with recurrent coronary event risk in patients with high HDL and C-reactive protein levels. PLoS One, 2013. 2. Huang Z, et al. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer. Mol Carcinog, 2014 Oct. 3. Jin Y, et al. Expression of plasminogen activator inhibitor-2 is negatively associated with invasive potential in hepatocellular carcinoma cells. Chin Med Sci J, 2013 Mar. 4. Zhou L, et al. Low expression of PAI-2 as a novel marker of portal vein tumor thrombosis and poor prognosis in hepatocellular carcinoma. World J Surg, 2013 Mar.

SERPINB2

Plasminogen activator inhibitor 2

serpin peptidase inhibitor, clade B (ovalbumin), member 2

HsT1201 antibody Monocyte Arg serpin antibody Monocyte Arg-serpin antibody Monocyte Arginine-serpin antibody Monocyte-derived plasminogen activator inhibitor antibody PAI antibody PAI-2 antibody PAI2 antibody PAI2_HUMAN antibody Placental plasminogen activator inhibitor antibody PLANH2 antibody Plasminogen activator inhibitor 2 antibody plasminogen activator inhibitor, type 2 antibody plasminogen activator inhibitor, type II (arginine-serpin) antibody serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2 antibody Serpin B2 antibody serpin peptidase inhibitor, clade B (ovalbumin), member 2 antibody Serpinb2 antibody Urokinase inhibitor antibody

P05120